Cyxone appoints Henrik Hang as CFO
9 juni, 2021
Henrik will succeed Ola Skanung, who has been the company's CFO since 2015. Ola hereby takes on the role of senior executive advisor in Cyxone and will continue to work within the company's management team.
"I am very pleased to welcome Henrik Hang as the new CFO of Cyxone. Henrik's broad experience within the field of financial management from roles in international companies and listed organizations will be of great value to us. I would also like to take this opportunity to extend my thanks to Ola Skanung who has done a fantastic job in recent years and who will continue to work with us in his new role as senior executive advisor”, says Tara Heitner, CEO of Cyxone AB.
“It will be very exciting to work with Cyxone as the company currently is in an expansive and interesting phase, partly in the development projects, but above all with the planned main market listing. I look forward to working with the rest of the team to develop Cyxone further.” says Henrik Hang.
Contact
Tara Heitner, CEO
Tel: +46 (0)70 781 88 08
E-post: tara.heitner@cyxone.com
About Cyxone
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is Mangold Fondkommission AB, +46 (0)8 503 015 50, ca@mangold.se. For more information, please visit www.cyxone.com
Ämnen i artikeln
Cyxone appoints Henrik Hang as CFO
9 juni, 2021
Henrik will succeed Ola Skanung, who has been the company's CFO since 2015. Ola hereby takes on the role of senior executive advisor in Cyxone and will continue to work within the company's management team.
"I am very pleased to welcome Henrik Hang as the new CFO of Cyxone. Henrik's broad experience within the field of financial management from roles in international companies and listed organizations will be of great value to us. I would also like to take this opportunity to extend my thanks to Ola Skanung who has done a fantastic job in recent years and who will continue to work with us in his new role as senior executive advisor”, says Tara Heitner, CEO of Cyxone AB.
“It will be very exciting to work with Cyxone as the company currently is in an expansive and interesting phase, partly in the development projects, but above all with the planned main market listing. I look forward to working with the rest of the team to develop Cyxone further.” says Henrik Hang.
Contact
Tara Heitner, CEO
Tel: +46 (0)70 781 88 08
E-post: tara.heitner@cyxone.com
About Cyxone
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is Mangold Fondkommission AB, +46 (0)8 503 015 50, ca@mangold.se. For more information, please visit www.cyxone.com
Ämnen i artikeln
Oljepriset
-992x558.png&w=3840&q=75)
-992x558.jpg&w=3840&q=75)
.jpg&w=3840&q=75)
Aktierekommendationer
-992x558.jpg&w=3840&q=75)
Placeras aktieanalyser
-992x558.png&w=3840&q=75)
-160x160.jpg&w=3840&q=75)
Oljepriset
Aktierekommendationer
Placeras aktieanalyser
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
-160x160.png&w=3840&q=75)
